Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes

Background/Objective: Insulin degludec (IDeg) is an ultra-long-acting analog with less daily variability compared to other basal insulins. In this retrospective study we examined 1-year efficacy and safety of IDeg in youth with type 1 diabetes (T1D). Subjects/Methods: Thirty-seven patients [11.7 ± 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Predieri, Barbara, Suprani, Tosca, Maltoni, Giulio, Graziani, Vanna, Bruzzi, Patrizia, Zucchini, Stefano, Iughetti, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115523/
https://www.ncbi.nlm.nih.gov/pubmed/30190702
http://dx.doi.org/10.3389/fendo.2018.00462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115523/
https://www.ncbi.nlm.nih.gov/pubmed/30190702
http://dx.doi.org/10.3389/fendo.2018.00462

Ejemplares similares